DeNovaMed, Inc.

The research presented here is a novel family of anti-infective compounds that disarm pathogens by blocking the synthesis of endotoxin.Min. inhibitory concentrations for this class are within the potency range of vancomycin for isolates of methicillin-resistant S. aureus (MRSA) and a wide variety of other Gram pos. pathogens.Lead compounds in this class have been shown to be nontoxic at 300 mg/kg in an acute toxicity study and have shown effectiveness in a mouse model of topical MRSA infection.The compound class also contains members with the ability to potentiate older drugs that are otherwise unusable in a clin. setting.The broad-spectrum potential of these novel anti-infective compounds is outlined.